Ovarian Cancer

Ovarian cancer is a devastating disease that has long challenged the medical community. However, the advent of poly(ADP-ribose) polymerase (PARP) inhibitors has ushered in a new era of hope for those battling this insidious malignancy. At Alfa Cytology, our team has been at the forefront of this groundbreaking field, dedicated to unlocking the full therapeutic potential of PARP inhibitors for ovarian cancer therapy.

PARP as a Therapeutic Target for Ovarian Cancer

PARP proteins play a crucial role in the DNA repair process, particularly in repairing single-strand breaks via the base excision repair pathway. Approximately 30% of all breast and ovarian cancer cases are caused by mutations in BRCA1 or BRCA2 genes. Ovarian cancer cells, especially those with BRCA1 or BRCA2 mutations, have impaired homologous recombination repair, making them more reliant on PARP for survival. PARP inhibitors have emerged as a promising class of targeted therapies for ovarian cancer. By inhibiting the PARP enzyme, PARP inhibitors induce synthetic lethality in tumor cells, leading to their selective destruction while sparing healthy tissues.

Fig. 1 Mechanism of action of PARP inhibitor for ovarian cancer. (Franzese E., et al. 2019)

PARP Inhibitor Development for Ovarian Cancer

The development of PARP inhibitors for ovarian cancer has seen significant advancements, and researchers are actively exploring combination strategies to further improve the efficacy of these targeted therapies. PARP inhibitors are being studied in combination with other targeted therapies, chemotherapies, and immunotherapies.

Therapy	AR agent	NCT	Phase
Combination Therapy	PARP Inhibitor Olaparib with the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363	NCT02208375
Combination Therapy	PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387	NCT02898207
Oral PARP Inhibitor	BMN 673	NCT02326844

Our Services

Through innovative research and advanced technology, Alfa Cytology delves into the mechanisms of PARP action and has the ability to help clients develop novel PARP inhibitors, as well as optimize the effectiveness of PARP inhibitors and identify their biomarkers, to accelerate the development of new ovarian cancer therapies.

Small Molecule Inhibitors Development

Optimizing potency, selectivity, and pharmacokinetic properties of small molecule PARP inhibitors.
Exploring novel structural scaffolds and mechanisms of PARP inhibition.

Peptide Inhibitor Development

Developing cell-penetrant, stable, and potent PARP-binding peptides
Novel peptide engineering techniques like cyclization, stapling, and site-specific modifications can enhance the drug-like properties of PARP-targeted peptides.

Our Ovarian Cancer Modeling Services

Ovarian Cancer In Vitro Models

Established Cancer Cell Lines
Primary Tumor Cell Cultures
3D Models
Organoids
Ovarian Cancer Tumor-on-a-chip
Patient-derived Explant Models

Ovarian Cancer In Vivo Models

Carcinogen-induced Tumor Models
Patient-Derived Xenografts (PDXs)
Genetically Engineered Mouse Model
Cell Line-Derived Xenografts
HEY, OVCA429, OVCA433, OCC1, OVCAR-3, SKOV-3, A2780-s, A2780-cp, OV2008, ES-2 and et al.
PBMC-Humanized Tumor Transplantation Models
Syngeneic Model

At Alfa Cytology, we are committed to advancing the field of ovarian cancer treatment through the development of cutting-edge PARP inhibitor therapies. If you are interested in exploring our services or collaborating on PARP inhibitor research, please don't hesitate to contact us. We are eager to discuss how we can support your research efforts and contribute to the ongoing progress in ovarian cancer care.

Reference

Franzese E., Centonze S., and et al. PARP inhibitors in ovarian cancer. Cancer Treatment Reviews. 2019, 73, 1-9.

For research use only. Not intended for any clinical use.